MFN Drug Pricing Policy Forces Companies To Rethink Selling Ex-US Rights

 
• By Mandy Jackson
  
Out-licensing ex-US rights could lower a drug's value because of MFN. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from United States